Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $135,036.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 900 shares of the company’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $150.04, for a total value of $135,036.00. Following the transaction, the insider now directly owns 18,202 shares in the company, valued at approximately $2,731,028.08. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Julie Cooke also recently made the following trade(s):

• On Monday, July 1st, Julie Cooke sold 10,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $140.19, for a total value of $1,401,900.00.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $145.69 on Friday. The firm has a market cap of $14.66 billion, a price-to-earnings ratio of 40.13 and a beta of 0.37. Neurocrine Biosciences, Inc. has a one year low of $96.67 and a one year high of $150.39. The stock’s 50-day moving average is $138.59 and its 200-day moving average is $137.49.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, May 1st. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $1.04 by ($0.62). The firm had revenue of $515.30 million during the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. On average, equities analysts expect that Neurocrine Biosciences, Inc. will post 4.2 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. First Horizon Advisors Inc. lifted its position in Neurocrine Biosciences by 10.5% during the 4th quarter. First Horizon Advisors Inc. now owns 782 shares of the company’s stock worth $103,000 after buying an additional 74 shares in the last quarter. Quadrant Capital Group LLC boosted its position in Neurocrine Biosciences by 3.9% during the fourth quarter. Quadrant Capital Group LLC now owns 2,075 shares of the company’s stock valued at $273,000 after purchasing an additional 78 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Neurocrine Biosciences by 3.2% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock valued at $333,000 after purchasing an additional 78 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in Neurocrine Biosciences by 0.6% in the 1st quarter. Commonwealth Equity Services LLC now owns 13,941 shares of the company’s stock valued at $1,923,000 after buying an additional 84 shares during the last quarter. Finally, Balentine LLC raised its holdings in Neurocrine Biosciences by 4.0% in the 4th quarter. Balentine LLC now owns 2,316 shares of the company’s stock valued at $305,000 after acquiring an additional 89 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Neurocrine Biosciences from $169.00 to $173.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Oppenheimer boosted their price target on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. Citigroup raised their price objective on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Wells Fargo & Company upgraded shares of Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $140.00 to $170.00 in a research report on Wednesday, April 24th. Finally, Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research report on Wednesday, May 1st. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $152.96.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.